# RNN 1st Gen Model Quest Diagnostics Incorporated Medical laboratories

Stock predictor AI models:
Subscribe >> Deal exit on
May 3, 2018
70.89% successful of 79 deals
$ 146.78 Last close price
at 29-oct-2021


Model's trade recommendations -0.34% Return for period

-2.54% Annual return

$13.77B Market Cap

β 0.71  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -0.34%
52wk return -10.25%
52wk Range
Sortino ratio -0.23
Sharpe ratio -0.21
Norm. RMSE 0.65%
Downside risk 10.04%
Volatility 0.00%
  • 2.00 (1.97%) Div (Yield)
  • BUY Analysts consensus recommendation

Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Industry sector: Medical

Sector classification: Medical laboratories

Deep Learning based analysis and prediction model for Quest Diagnostics Incorporated (DGX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for DGX model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for DGX.

Model is being retrained on a daily basis.

Float 133M
P/E 17.36
Shares Outstanding 136M
% Held by Insiders 1.79%
% Held by Institutions 88.84%
EPS (last reported FY) $5.40
EPS (last reported Q) $1.52
EPS, estimated (last reported Q) $1.52
Total revenues $8 B
Net income $1 B